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NEW RESEARCH

Development of a Symptom-Focused Model to Guide
the Prescribing of Antipsychotics in Children and
Adolescents: Results of the First Phase of the Safer
Use of Antipsychotics in Youth (SUAY) Clinical Trial
Robert B. Penfold, PhD, Ella E. Thompson, BA, Robert J. Hilt, MD, Nadine Schwartz, MD,
Adelaide S. Robb, MD, Christoph U. Correll, MD, Douglas Newton, MD,
Kelly Rogalski, MD, Marian F. Earls, MD, Robert A. Kowatch, MD, Arne Beck, PhD,
Bobbi Jo H. Yarborough, PsyD, Stephen Crystal, PhD, Benedetto Vitiello, MD,
Kelly J. Kelleher, MD, MPH, Gregory E. Simon, MD
Objective: To develop a new approach to prescribing guidelines as part of a pragmatic trial, Safer Use of Antipsychotics in Youth (SUAY; ClinicalTrials.gov Identiﬁer: NCT03448575), which supports prescribers in delivering high-quality mental health care to youths.
Method: A nominal group technique was used to identify ﬁrst- to nth-line treatments for target symptoms and potential diagnoses. The panel included
US pediatricians, child and adolescent psychiatrists, and psychopharmacology experts. Meeting materials included information about Medicaid review
programs, systematic reviews, prescribing guidelines, and a description of the pragmatic trial. Afterward, a series of 4 webinar discussions were held to
achieve consensus on recommendations.
Results: The panel unanimously agreed that the guideline should focus on target symptoms rather than diagnoses. Guidance included recommendations for ﬁrst- to nth-line treatment of target mental health symptoms, environmental factors to be addressed, possible underlying diagnoses that should
ﬁrst be considered and ruled out, and general considerations for pharmacological and therapeutic treatments.
Conclusion: Prescribing guidelines are often ignored because they do not incorporate the real-world availability of ﬁrst-line psychosocial treatments,
comorbid conditions, and clinical complexity. Our approach addresses some of these concerns. If the approach proves successful in our ongoing pragmatic trial, Safer Use of Antipsychotics in Youth (SUAY), it may serve as a model to state Medicaid programs and health systems to support clinicians in
delivering high-quality mental health care to youths.
Clinical trial registration information: Safer Use of Antipsychotics in Youth; http://clinicaltrials.gov/; NCT03448575
Key words: antipsychotic, guidelines, consulting, accessibility
J Am Acad Child Adolesc Psychiatry 2022;61(1):93−102.

eginning in the mid-1990s, rates of prescribing
antipsychotic medications to children and adolescents have grown tremendously1-7 and remain
high in some Medicaid and commercially insured populations.6,8-10 Signiﬁcant decreases have been reported in populations with targeted programs to reduce use.11-13 The vast
majority of antipsychotic use in youths aged 4 to 17 years is
not for psychotic disorders, mania, irritability associated
with autism, or tic disorders, which are the regulatory indications for antipsychotic use; rather, antipsychotics are prescribed the most for youths diagnosed with attentiondeﬁcit/hyperactivity disorder (ADHD), conduct disorder
(CD) or oppositional deﬁant disorder (ODD), and/or

B

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 61 / Number 1 / January 2022

impulsive aggression.8,14-17 In 1 study, 66.9% of boys aged
6 to 11 years who were prescribed an antipsychotic had a
diagnosis of ADHD and 43.1% had a diagnosis of CD or
ODD.8 Given these data, there is widespread concern that
antipsychotics are over-prescribed.18
One of the greatest concerns about antipsychotic use is
the signiﬁcant weight gain that patients experience, which is
associated with incident diabetes mellitus in youths and cardiovascular disease and premature mortality in adults.19-26
Individual SGAs carry different risks, with clozapine and
olanzapine considered most strongly associated with weight
gain, and lurasidone, aripiprazole, brexpiprazole, cariprazine, and ziprasidone associated with lower weight gain,
www.jaacap.org
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although several studies have shown that all second-generation antipsychotics are associated with weight gain to varying degrees.22,27-32 There is concern that youths may be even
more vulnerable to the metabolic side effects of these medications than adults and that, with continued treatment, these
negative side effects propagate through the lifespan—potentially leading to higher risk of cardiovascular disease and
increased premature mortality.1,17,33-35 Medication side
effects such as extrapyramidal symptoms and sedation may
also impair functioning in youths more than in adults.36,37
In this paper, we report on the results of a consensus
panel tasked with recommending appropriate prescribing of
antipsychotics to youths in the context of large health care
systems and supportive services. These recommendations
are part of a multi-component approach to minimizing
inappropriate antipsychotic prescribing. We argue that our
approach addresses many of the reasons why antipsychotics
appear to be over-prescribed: lack of access to empirically
supported psychosocial treatments; guidelines that are
inﬂexible, are silent on the psychological and physical
comorbidities that youths experience, and fail to acknowledge the availability of ﬁrst-line psychosocial treatments;
difﬁculty parents/guardians face in navigating access to primary care and specialty mental health services; and geographic and logistical barriers to accessing mental health
services regularly. This approach was developed as part of a
pragmatic clinical trial funded by the National Institute of
Mental Health called Safer Use of Antipsychotics in Youth
(SUAY).38 The approach is intended to be most useful to
pediatricians and primary care physicians, as they may treat
lower volumes of patients with severe emotional disturbance; however, the guidelines are also relevant to child
and adolescent psychiatrists in their own clinical practices
and in the consultative roles that they often are called upon
to play.
Safer Use of Antipsychotics in Youth (SUAY)

SUAY is a pragmatic clinical trial that is designed to test an
approach to improving the targeted use of antipsychotics in
youths aged 4 to 17 years.38 The approach was motivated
by the Second Opinion program implemented in Washington State for youths insured by Medicaid, which produced
a 51% relative decrease in antipsychotic use.13 The core elements of the intervention are as follows: (1) prescribing recommendations developed by our expert consensus panel;
(2) clinical decision support (electronic health record
[EHR] based best practice alert) integrated into the practice ﬂow; (3) review of antipsychotic prescription orders and
feedback to the prescribing clinician by a child and adolescent psychiatrist within 10 days of the order (according to
the treatment algorithm); (4) behavioral health navigation
94
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for psychosocial treatment alternatives; and (5) improved
access to psychosocial therapies via use of video conferencing. A full description of the study protocol is available elsewhere.39 The methods and results presented in the current
article focus on the ﬁrst of the 5 core elements (prescribing
recommendations developed by an expert consensus panel)
described, and do not directly address the others.
Rationale for a New Approach to Antipsychotic
Prescribing Guidelines

In its Choosing Wisely recommendations, the American Psychiatric Association lists as its ﬁfth recommendation:
Don’t routinely prescribe an antipsychotic medication to treat
behavioral and emotional symptoms of childhood mental disorders in the absence of approved or evidence supported
indications.40

This carefully worded recommendation acknowledges
that not all antipsychotic prescribing for emotional and behavioral disturbances is inappropriate. Importantly, there are a
number of reasonable algorithms for antipsychotic prescribing
to youths41-46; however, there are 2 fundamental gaps that we
address in our current recommendations to implement such
guidelines: (1) how to support clinicians in most effectively
using the algorithms, and (2) how to increase access to psychosocial and pharmacological treatments that existing guidelines recommend and that are supported by empirical
evidence as part of ﬁrst-line treatment. Below we address the
fundamental issues of implementing the guidelines.47-54
Existing algorithms/guidelines for the use of antipsychotic medications include the Texas Medication Algorithm
Project (TMAP),43 Treatment Recommendations for the
use of Antipsychotics for Aggressive Youth (TRAAY),41 the
Practice Parameter for the Use of Atypical Antipsychotic
Medications in Children and Adolescents46 from the American Academy of Child and Adolescent Psychiatry (AACAP),
and the Treatment of Maladaptive Aggression in Youth (TMAY) guidelines developed through a systematic evidence
review and consensus panel.55,56 Each of these guidelines
provides thoughtful, reasonable, and practical guidance to
clinicians on how to prescribe antipsychotic medications.
However, uptake of these guidelines and recommendations
is thought to be lower than desirable, as shown by several
observational studies and meta analyses8,10,16,57 of antipsychotic prescribing frequencies.
There are several reasons for this gap. First, most clinicians regard guidelines as “cookbook” medicine that is not
tailored to individual patient needs. Guidelines can be difﬁcult to adapt to patient needs because a guideline cannot
account for every possible clinical scenario or patient context, preferences, and values. The effective use of treatment
Journal of the American Academy of Child & Adolescent Psychiatry
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algorithms is also complicated by these guidelines failing to
account for psychiatric comorbidities, which are more the
rule than the exception for patients.58 Treatment guidelines
generally remain silent on the question of their application
to patients with multiple health conditions.50 An ideal algorithm would provide ﬂexibility and “step outs” to be
patient/family centered.
A second reason for discordance between guidelines and
care delivery is a lack of access to recommended ﬁrst-line
treatments. For example, the TRAAY guideline recommendation #3 is to begin with psychosocial and educational
interventions.41 Similarly, in the TMAY guidelines, recommendation 7 is to “Provide psychoeducation for patients
and families (Grade of Evidence: B; Strength of Recommendation: Very Strong)”55; recommendation 10 is to
“Provide or assist the family in obtaining evidence-based
parent and child skills training during all phases of care
(Grade of Evidence: A; Strength of Recommendation: Very
Strong)”; and recommendation 11 is to “Engage the child
and family in taking an active role in implementing psychosocial strategies and help them to maintain consistency
(Grade of Evidence: B; Strength of Recommendation: Very
Strong).”56 However, access to clinicians providing these
services may be limited in terms of geography or capacity.59,60 Children and adolescents living outside of major
metropolitan and surrounding areas are particularly underserved in access to such services.61-63 These disparities in
access to and quality of care have been noted most prominently for child and adolescent psychiatrists,59,64,65 but are
relevant to other child and adolescent mental health specialists as well.66-68 Furthermore, a lack of local providers may
cause parents/guardians to delay seeking and accessing care
until behavioral issues become so severe that an antipsychotic is prescribed when an earlier psychosocial intervention or different medication would have prevented the
more severe behavior and associated dysfunction.
Thus, although many pediatricians and primary care
physicians would prefer their patients to use psychosocial
therapies, they may resort to prescribing antipsychotics to
provide the patient/family with any effective and fast or easily accessible treatment as an alternative to no treatment.
New approaches to meeting this demand are needed to
increase the use of recommended psychosocial interventions.69 With appropriate psychotherapies, engaging the
family in constructive management of problematic behaviors, the use of antipsychotics may be avoided or minimized,
and families gain the opportunity to learn new skills in managing their children’s symptoms and needs.70
Finally, existing guidelines tend to begin with a single
condition or diagnosis, such as ADHD, CD, or ODD, and
recommend a series of treatment steps for that individual
Journal of the American Academy of Child & Adolescent Psychiatry
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diagnosis. The majority of pediatric patients presenting
with a psychiatric disorder have other “comorbid” disorders
that are difﬁcult to address with simple guidelines.71 Guidelines are lacking that could help a provider to assess whether
a speciﬁc treatment, such as an antipsychotic, is likely to be
the most appropriate choice for a clinical circumstance
more complex than a single diagnosis. The broad range of
behavioral and mood disturbances for which antipsychotics
are used suggests that an algorithmic approach to minimizing the use of antipsychotics in youths should include
expert child and adolescent psychiatrist support as an integral component. Primary care physicians and pediatricians
frequently report a desire for more support in managing
behavioral health conditions.72 However, a key difﬁculty
in providing such support is how to make it accessible and
timely.
METHOD
Consensus Panel of Child Psychiatrists, Pediatricians,
and Health Services Researchers

A full-day, face-to-face summit of clinical experts was held
at the Kaiser Permanente Center for Total Health in Washington, DC on July 28, 2016. Experts serving as panelists
included pediatricians, child and adolescent psychiatrists,
and psychopharmacology experts from across the United
States. Supplement 1, available online, provides more
detailed biographical information about panelists.
Panelists were provided with a series of materials in
advance of the summit to help them prepare. Advance
materials included the following: the SUAY study scientiﬁc
approach; information about the Second Opinion program that inspired the SUAY approach13; previous literature (see Supplement 2, available online) and systematic
reviews73-75; and recommendations by the AHRQ,76
American Psychiatric Association,77 American Academy
of Child and Adolescent Psychiatry,46 and American
Academy of Pediatrics.78 We also conducted an independent systematic review of clinical trials involving children
and adolescents that was distributed to panelists along
with hyperlinks to the manuscripts included in our ﬁnal
review.
Systematic Review of Evidence

The systematic review was conducted according to version
5.1 of the Cochrane criteria.79 We searched Embase and
PubMed/Medline to identify all randomized trials, openlabel trials, and meta-analyses reporting results for all ﬁrstgeneration and second-generation antipsychotic medications
available in the United States on or before May 23, 2016,
and conducted with participants less than 18 years of age.
www.jaacap.org
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Unpublished (non peer-reviewed) studies were excluded so
as to focus on the highest-quality evidence. The search
terms involved a combination of generic medication name,
symptom, and child or adolescent participants. An example
search would be: “cariprazine AND aggression AND (child
OR adolescent). This search was repeated for the combination of 19 generic medication names and 16 conditions/symptoms (anxiety, depression, posttraumatic stress,
aggression, disruptive, eating, sleep, insomnia, mood lability, dysregulated, mania, obsession, compulsion, psychosis,
suicidal ideation, and tics) for a total of 304 searches. The
generalized search strategy syntax was as follows:
(aripiprazole OR asenapine OR brexpiprazole OR cariprazine OR
clozapine OR ﬂuphenazine OR haloperidol OR iloperidone OR
loxapine OR lurasidone OR olanzapine OR paliperidone OR
perphenazine OR pimozide OR quetiapine OR risperidone OR
thiothixene OR triﬂuoperazine OR ziprasidone)
AND (anxiety OR depression OR ﬂashbacks OR nightmares
OR trauma OR disruptive OR aggressive OR impulsive OR
dysregulated OR eating OR anorexia OR bulimia OR sleep
OR insomnia OR mania OR hypomania OR “mood lability”
OR irritability OR “mood swings” OR obsessive OR compulsive OR psychosis OR bipolar OR substance OR suicidal OR
tics OR Tourette’s OR autism OR pervasive)
AND (child* OR adolescent)

The principal investigator and 3 research assistants
divided this work and compiled the results. After de-duplication, the initial list of studies included 275 manuscripts.
In the next phase, we eliminated all studies that were
not randomized trials, open-label trials, or meta-analyses
(n = 146), leaving 129 manuscripts to review for eligibility.
Of these, 71 were eliminated, leaving 58 studies to formally
evaluate using the Cochrane criteria.79 Each study was evaluated according to risk of: selection bias, performance bias,
detection bias, attribution bias, reporting bias, and other
bias. Version 1 of the Cochrane risk of bias tool was used.80
Risk of bias was rated as low, high, or unclear. A spreadsheet
template was completed by each reviewer with their rating
on each dimension and a snippet of text copied from the
manuscript supporting their rating. After review, 36 studies
were judged to be of sufﬁcient quality to include in the
information packet for consensus panel members. Excluded
studies had at least 1 domain on the risk of bias tool rated as
“high.” Panelists were provided with a spreadsheet ﬁle summarizing the review on each Cochrane criterion as well as a
hyperlink to a portable document ﬁle (*.pdf) copy of the
original manuscript. Manuscripts were grouped by symptom/diagnosis to facilitate in-person discussion. A supplementary list of references provided to panelists is available
in Supplement 2, available online.
96
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Summit Organization and Approach

The summit began with introductions, an overview of the
pragmatic trial, a brief review of the materials distributed
prior to the meeting, an introduction to the nominal group
technique81,82 for reaching consensus, and the goals of the
meeting.
The nominal group technique involves 4 stages: idea
generation, recording ideas, discussing ideas, and voting on
ideas. Panelists were provided with “voting worksheets” that
listed diagnostic categories for each row and a column for
idea generation and idea ranking. The principal investigator
(RP) and facilitator (ET) initially presented the panelists
with a list of diagnostic categories for which antipsychotic
medications had been prescribed according to any clinical
trial or observational study (including case reports) identiﬁed while conducting the systematic review of evidence.
That list included the 16 conditions/symptoms used to conduct the systematic review. After an initial round of idea
generation and discussion, it was suggested that “violent ideation” be added to the list, and the vote on this addition was
unanimous.
Panelists were then asked to generate up to 5 ideas for
antipsychotic prescribing scenarios (eg, not responding to
current antidepressant) that they would endorse most
strongly for each condition/symptom category, and then to
prioritize/rank these for discussion. We then recorded all
unique ideas for clinical scenarios and held a group discussion. Each of the 16 symptom domains was discussed separately with the goal of identifying the following:
environmental factors to address related to the symptom;
any underlying diagnoses with preferred treatments before
considering prescribing an antipsychotic; underlying diagnoses to consider ﬁrst; and general antipsychotic medication considerations related to the symptom or potential
diagnosis.
Following the in-person summit, a series of four 1-hour
weekly webinar discussions between panelists were held to
reﬁne the resulting recommendations. Panelists reviewed
and provided input on draft guidance materials outside of
the webinars via email. These efforts culminated in the
development of a series of expert opinions regarding the
ﬁrst- to nth-line treatment of pediatric conditions treated
with antipsychotics. At the ﬁnal webinar meeting, panelists
were asked to vote on their omnibus approval of the prescribing guidance.
RESULTS
Much of the discussion involved panelists considering how
best to identify and to structure consultations and reviews
by child and adolescent psychiatrists. The principal
Journal of the American Academy of Child & Adolescent Psychiatry
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investigator and Dr. Robert Hilt described the mandatory
review process in Washington State for Medicaid youths,
and identiﬁed the strengths and weaknesses of that program
(as well as similar programs across the United States). The
ensuing discussion among panelists revolved around the following: difﬁculties arriving at a correct diagnosis for youths;
shortcomings of the American mental health system; and
the inﬂexibility of existing guidelines for prescribing antipsychotic medications. A panelist suggested that reviews
should focus on the primary symptom that the prescriber is
trying to treat—especially in the absence of actually seeing
the patient and in the absence of standardized instrument
scores or formal diagnostic interviews. The panel voted
unanimously that the guidance should be organized around
target symptoms (ie, principal complaint) rather than diagnoses. There were 3 primary reasons for focusing on symptoms. First, arriving at the correct diagnosis can be difﬁcult,
and requiring revisions over time for developing children.
Second, the anticipated target audience for their recommendations, primary care providers, and pediatricians are often
less conﬁdent in making a mental health diagnosis. Third,
there was some concern about prescribers adjusting diagnoses to avoid the inconvenience of triggering a review (eg,
entering a diagnosis of bipolar disorder to justify the prescribing of an antipsychotic for moderate mood lability).
Consensus panel efforts culminated in a series of guidance
for ﬁrst- to nth-line treatment of target mental health presentations. Table 1 summarizes the organizational construct developed for identifying the target symptom and possible

underlying diagnoses within each of these categories. Full consensus panel guidance includes identifying and addressing environmental factors, possible underlying diagnoses that should
ﬁrst be considered and ruled out, and general considerations for
pharmacological and therapeutic treatments for each target
symptom or principal complaint. For instance, the consensus
panel recommended never prescribing antipsychotics for certain cases, including the following: anxiety alone, insomnia,
mood swings or lability or irritability without mania, substance
misuse, or suicidal ideation in the absence of psychosis or severe
treatment-resistant depression. This particularly strong language concerning “never prescribe” for certain clinical scenarios
was again unanimously endorsed by the panelists with the rationale that the risk beneﬁt ratio for antipsychotics was unfavorable in the cases indicated. Supplement 3, available online,
outlines the treatment steps recommended by the panel for
each symptom.
The consensus panel also assisted in developing a case
review form for consultations to be used in the pragmatic
trial. Dose optimization of alternative pharmacotherapies
and a history of current and prior medications (including
the use of lower-risk medications) and psychotherapeutic
interventions were recommended to be reviewed and discussed during consultations as needed. Finally, the panel
discussed the use of navigation and best practice alerts as
part of the effective implementation of the system.
To summarize, the consensus panel identiﬁed several
key components for a best practice approach to safer and
targeted use of antipsychotics via consultation:

TABLE 1 Organization of Clinical Guidance Tablesa
Target symptom
Anxiety
Depression
Dissociation ﬂashbacks, nightmares
Disruptive, aggressive, impulsive, dysregulated behaviors
Eating disorders
Insomnia
Mania
Mood lability, irritability, mood swings (without mania)
Obsession and compulsion
Psychosis
Substance misuse
Suicidal ideation
Tics
Violent ideation

Examples of possible related diagnoses
GAD, SAD, panic disorders
MDD, persistent depression
PTSD
ODD, CD, ADHD
AN, BN
Various mental health disorders
Bipolar disorder I/II
DMDD, ODD, CD
OCD
Schizophrenia, schizoaffective disorders,
SUD
Depression
Simple tics, TS
Bipolar disorder I/II, schizophrenia, SUD

Note: ADHD = attention-deﬁcit/hyperactivity disorder; AN = anorexia nervosa; BN = bulimia nervosa; CD = conduct disorder; DMDD = disruptive mood
dysregulation disorder; GAD = generalized anxiety disorder; MDD = major depressive disorder; OCD = obsessive-compulsive disorder; ODD = oppositional deﬁant disorder; PTSD = posttraumatic stress disorder; SAD = social anxiety disorder; SUD = substance use disorder; TS = Tourette syndrome.
a
See Supplement 3, available online, for detailed tables.
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 Identify the target symptom(s)/behavior(s) that chieﬂy
concern the patient/parent(s)/guardian(s);
 Identify and address potential triggers;
 Identify and speciﬁcally address potential diagnoses (eg,
rule out psychosis);
 Take a history of the type of, and response and tolerability
to, current and prior medications and psychosocial therapies used;
 Consider the potential for dose optimization of the
patient’s current medications and/or use of alternative or
additional/adjunctive medications not in the antipsychotic class (eg, stimulants, antidepressants, a-adrenergic
agonists);
 Consider use of lower-risk medications (eg, stimulants,
antidepressants, a-adrenergic agonists);
 Consider the potential for increased use of or changes to
psychosocial therapy. This may be achieved through the
use of mental health navigators, use of televideo therapy,
and reminder/review protocols.

DISCUSSION
A number of Medicaid programs across the country (eg,
South Florida, Washington, Massachusetts) have implemented or are considering pharmacy management programs
that include consultation with a child and adolescent psychiatrist as a core component.13,83-85 Integrated health systems, such as Kaiser Permanente, also offer telepsychiatry
consultations to pediatricians and primary care physicians.
The recommendations developed by the expert panel in this
study—especially the focus on target symptoms—can be
used to guide the discussion between the prescribing and
consulting physicians most effectively.
A second beneﬁt of the targeted symptoms approach in
this guideline is that the recommendations are ﬂexible and
mindful of comorbid psychiatric and physical conditions.
In this way, the guideline is more useful to clinicians facing
complicated prescribing choices.
A third beneﬁt of this guideline approach (supported by
best practice alerts, care navigation, and expedited access to
psychotherapy) is that it can be scaled to larger populations of
patients and larger (more distant) geographic populations of
youths because child and adolescent psychiatrist time, despite
being a limited resource, can be efﬁciently and effectively
deployed to improve treatment by supporting consultation
with record reviews or telephone consultations for only those
cases in which prescribing falls outside of guideline care.
Finally, clinicians might be concerned that a targeted
symptom approach could delay the diagnosis of a disorder
or that a potential unintended consequence of a focus on
98
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each targeted symptom could be an increase in multiclass
polypharmacy. However, the guidance in every symptom
class involves the following process: (1) identify the target
symptoms, (2) rule out potential diagnoses, (3) review current and past treatments (eg, medications and psychotherapies), and (4) consider treatment alternatives (eg, dose or
medication changes, lower-risk medications, psychotherapy). As such, the guidance developed here provides a
framework for consulting child and adolescent psychiatrists
to work with prescribers in arriving at an effective treatment
plan for the principal complaint. The process begins by
honing-in on what the clinician is trying to achieve with the
antipsychotic medication (target symptom) and works
through whether a different diagnosis might ﬁt better and
whether current medication doses might be increased or a
return to previously successful medications might be considered. The program that inspired the approach developed
here reported decreases in polypharmacy after it began.13
Clinicians may also be concerned that the proposed
guidance unnecessarily impinges on the professional autonomy of practitioners. We originally proposed a “hard stop”
(similar to Medicaid programs) whereby clinicians would
not be able to order the medication without a second opinion consult from a child and adolescent psychiatrist (regardless of whether the ordering clinicians were themselves
psychiatrists). We interviewed physicians in 2 health systems about how best to implement the program, and concluded that a “soft stop” would be preferable so as to
engender a culture of collegiality.86
We would advocate for health system administrators
and department chiefs to make local decisions on how
strongly to push the guidance. We assembled a multi-disciplinary team of experts and report on their recommendations. The suite of SUAY intervention is designed to “make
the right thing easy to do” but is also designed to change
prescribing behavior.
This study focused on an approach to supporting the
targeted prescribing of antipsychotics. The speciﬁc recommendations for that class of medication do not necessarily
generalize broadly to other medication classes. However,
the approach—identify target symptoms, step through
lower-risk medications, facilitate psychosocial interventions,
and make expert advice available—can be generalized to
other medication classes and therapies. Also, the consultation and guideline focused on the use of a certain medication class, in this case antipsychotics, but did not address
the level of outcomes per se (eg, on standardized instruments
of symptom severity and/or functioning). Thus, measurement-based care should increasingly be used, in that both
symptomatic, but also patient-reported and family-centered
measurements and self-reports, are incorporated in the
Journal of the American Academy of Child & Adolescent Psychiatry
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assessment of the adequacy, effectiveness, tolerability, and
overall acceptability of speciﬁc-treatment approaches. We
acknowledge that the systematic review of evidence is now
somewhat dated; however, the published evidence for prescribing antipsychotics to children and adolescents for conditions other than psychotic disorders, bipolar disorder,
autism spectrum disorder, and developmental disability
remains limited. Also, we did not attempt to qualify the
strength of evidence for panelists prior to the in-person
meeting. The stepped treatment recommendations for the
multiple disorders covered in the guidance tables are based
on expert consensus in addition to review by the panel of
the treatment literature and guidelines for each disorder.
Although development of this approach to reviewing
antipsychotic prescriptions included a broad representation
of pediatricians, child and adolescent psychiatrists, and
experts in psychopharmacology in the United States, other
stakeholders were not part of the guideline development. In
particular, we did not directly incorporate the input of
parents, guardians, and youths. However, we did conduct a
series of focus groups and telephone interviews with families
at each of the 4 health systems participating in the trial to
inform development of the overall SUAY program. Qualitative information reported by children, adolescents, and
parents/guardians regarding their experience accessing mental health care, being prescribed an antipsychotic, medication side effects, and changes in behavior and functioning
(both positive and negative) was incorporated into the study
protocol for offering supportive services—including help
ﬁnding psychosocial services close to home and accessing
therapy via televideo. Should the SUAY trial yield beneﬁcial
outcomes in terms of more targeted antipsychotic prescribing, the ultimate and reﬁned guideline (and supporting
approach) will be informed and vetted by multiple additional stakeholders, including patients, families, and payers.
Antipsychotic prescribing that focuses on target symptoms rather than diagnoses was unanimously endorsed by a
panel of experts and may hold signiﬁcant promise as a strategy for improving safe and judicious antipsychotic prescribing. Such an approach may be especially promising when
implemented as part of a multicomponent intervention that
deploys organizational inﬂuence processes to integrate prescribing recommendations, clinical decision support, and
timely specialty review of prescription orders with collegial
feedback; behavioral health navigation; and improved access
to psychosocial therapies, including the use of telemedicine.
This multicomponent approach is currently being tested in
the SUAY trial, with the primary outcome being duration
of antipsychotic use among youths initiating treatment.
The study will also measure negative unintended consequences including hospital admissions, emergency
Journal of the American Academy of Child & Adolescent Psychiatry
Volume 61 / Number 1 / January 2022

department visits, and suicide attempts. If the approach
proves successful at increasing or intensifying the use of psychosocial interventions before antipsychotic medication use
and minimizing the duration of antipsychotic treatment
once started, it may serve as a model to state Medicaid programs and health systems as a way to support pediatricians
and primary care physicians in delivering high-quality mental health care to youths.
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